NU670 naltrexone, methadone and buprenorphine compared

The prompt sets up its own answer in the first sentence and the setup is easy to walk past. It observes that naltrexone is used for addiction and impulse control and occasionally for self-harm behaviours and weight loss, and then asks how its mechanism of action aids addiction treatment. Those apparently unrelated uses are the clue: they share a mechanism, because opioid receptor antagonism blunts the endogenous opioid signalling involved in reward and reinforcement generally, not only in opioid use. A strong answer starts from that and explains why the same drug reduces heavy drinking days in alcohol use disorder, blocks the effect of exogenous opioids, and has a rationale in behaviours nobody would call substance use. Answering only for opioids has answered a narrower question than the one asked and left the prompt's own framing unused. Use the prompt's own list as the structure for the first paragraph and the answer writes itself.

Mechanism needs to be precise rather than gestural, because this is a psychopharmacology discussion. Naltrexone is a competitive antagonist with high affinity at the mu opioid receptor and activity at kappa and delta. In opioid use disorder it occupies the receptor so an agonist cannot produce an effect, which removes the reinforcement rather than reducing the craving directly. In alcohol use disorder the pathway is indirect: alcohol increases endogenous opioid release, which disinhibits dopaminergic reward signalling, and blocking that limb reduces the rewarding effect of drinking and thereby reduces heavy drinking rather than necessarily producing abstinence. Say that distinction plainly, because it is the reason patients on naltrexone for alcohol are usually told to keep taking it if they drink rather than to stop. It is also the reason the drug is described as reducing heavy drinking days rather than producing abstinence, which is a specific claim worth citing rather than paraphrasing loosely.

The comparison in the second half needs a structure or it becomes two descriptions side by side. Use the four elements the prompt names as headings and answer both drugs under each, which forces genuine contrast. Both are used in opioid use disorder; buprenorphine is also used in pain and neither is a treatment for stimulant use, which is worth saying because a comparison implies a shared indication. Mechanistically methadone is a full mu agonist with NMDA antagonist activity and a long, variable half life, while buprenorphine is a partial mu agonist with very high receptor affinity and slow dissociation, usually combined with naloxone. That single difference between full and partial agonism generates most of the practical contrasts that follow. Say that explicitly early in the comparison, because everything from overdose risk to take-home supply follows from it and a reader who has that difference can predict most of the rest.

Contraindications and cautions are where the answer becomes clinical rather than pharmacological. For methadone the concerns are QT prolongation and torsades, respiratory depression particularly during induction and with concurrent benzodiazepines or alcohol, and the interaction burden of a drug metabolised through several cytochrome pathways. For buprenorphine the defining problem is precipitated withdrawal if it is given while a full agonist still occupies the receptor, which is what drives induction timing and the newer low-dose initiation approaches. Hepatic impairment matters for both. For naltrexone, the contraindication that must appear is current opioid use or physiological dependence, since administering an antagonist precipitates withdrawal, and the requirement for an opioid-free interval before initiation follows from that. Naming the mechanism behind each contraindication rather than listing them is what turns this section from recall into pharmacology, and it takes no more words to do. Hepatic function is the one shared caution across all three and is worth a line of its own.

The pros and cons should be written from the patient's position rather than the pharmacology textbook's. Methadone's ceiling-free efficacy and long history suit patients with high tolerance and unstable use, but daily attendance at a licensed programme is a real burden and a real barrier for someone working or without transport. Buprenorphine's partial agonism gives a ceiling on respiratory depression and allows office-based prescribing and take-home supply, at the cost of induction difficulty and sometimes inadequate coverage at higher tolerance. Naltrexone requires no controlled substance and no withdrawal risk in the medication itself, but requires abstinence before starting and has weaker retention evidence in opioid use disorder than the agonists. Retention is the outcome that matters most, and saying so is the mark of a clinically informed answer. Say which of these barriers you have actually seen operate, if you have, since a lived observation is what a discussion thread can build on.

On execution, this is a discussion requiring peer-reviewed journal evidence, so cite for the comparative claims rather than for the definitions. Two hours is the stated estimate and a well-structured post of moderate length beats a long one. Two things will lift the post above the thread: naming the stigma and regulatory history that shaped access to these medications, since that explains why the least effective option is sometimes the most available, and stating a position on which medication you would reach for first and in what circumstances. A comparison that ends without a preference has described three options and helped nobody choose between them. Say what would change your first choice, and the post gives the thread somewhere to go rather than a summary to agree with. Retention is the outcome the literature reports most consistently, so anchor the preference there rather than on efficacy in the abstract.